文献速递心脑血管急症

糖尿病患者复杂经皮冠状动脉介入治疗中血管内 imaging 与造影引导的比较:一项随机临床试验的二次分析

Intravascular Imaging and Angiography Guidance in Complex Percutaneous Coronary Intervention Among Patients With Diabetes: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2024-06-03
一句话结论在复杂PCI中,血管内成像引导较造影引导显著降低非糖尿病患者靶血管失败风险(HR 0.41),但糖尿病患者无显著获益(HR 0.97);糖尿病患者中仅血糖控制良好(HbA1c≤7.5%)且经血管内成像实现支架优化者缺血事件风险较低(HR 0.31)。

该研究为RENOVATE-COMPLEX-PCI试验的预设二次分析,纳入韩国20个中心2018年5月至2021年5月接受复杂PCI的1639例患者(平均年龄65.6岁,男性79.3%),按2:1随机分配至血管内成像引导组或造影引导组。主要终点靶血管失败(TVF)在糖尿病患者中发生率显著高于非糖尿病患者(HR 1.86,95%CI 1.33-2.60,P<.001)。非糖尿病患者中,血管内成像引导组TVF发生率显著低于造影引导组(4.7% vs 12.2%;HR 0.41,95%CI 0.25-0.67,P<.001);糖尿病患者中两组无显著差异(12.9% vs 12.3%;HR 0.97,95%CI 0.60-1.57,P=.90);血管内成像与糖尿病的交互作用显著(P for interaction=.02)。糖尿病患者中,仅血糖控制良好(HbA1c≤7.5%)且经血管内成像实现支架优化者未来缺血事件风险较低(HR 0.31,95%CI 0.12-0.82,P=.02)。作者认为,复杂PCI中应关注血管内成像支架优化和血糖控制以改善结局。

要点

  • 糖尿病患者复杂PCI后TVF发生率显著高于非糖尿病患者(HR 1.86,95%CI 1.33-2.60,P<.001)。
  • 非糖尿病患者中,血管内成像引导较造影引导显著降低TVF(4.7% vs 12.2%;HR 0.41,95%CI 0.25-0.67,P<.001)。
  • 糖尿病患者中,血管内成像引导与造影引导的TVF风险无显著差异(12.9% vs 12.3%;HR 0.97,95%CI 0.60-1.57,P=.90)。
  • 血管内成像与糖尿病对TVF风险存在显著交互作用(P for interaction=.02)。
  • 糖尿病患者中,仅HbA1c≤7.5%且经血管内成像实现支架优化者缺血事件风险较低(HR 0.31,95%CI 0.12-0.82,P=.02)。

适用人群与场景

  • 纳入RENOVATE-COMPLEX-PCI试验中接受复杂PCI的患者,来自韩国20个中心,2018年5月至2021年5月入组,共1639例(平均年龄65.6岁,男性1300例占79.3%),其中糖尿病617例(37.6%)。

诊断标准与关键阈值

  • 糖尿病定义及HbA1c≤7.5%的血糖控制良好界值见原文。
  • 主要终点靶血管失败(TVF)定义为心源性死亡、靶血管相关心肌梗死或靶血管血运重建的复合终点。

处置流程与药物剂量

  • eligible患者按2:1比例随机分配接受血管内成像引导的PCI或造影引导的PCI。
  • 糖尿病患者中,仅血糖控制良好(HbA1c≤7.5%)且经血管内成像实现支架优化者显示较低缺血事件风险(HR 0.31,95%CI 0.12-0.82,P=.02)。

研究设计与关键结果

  • 研究类型:RENOVATE-COMPLEX-PCI随机对照试验的预设二次分析,研究者发起、开放标签、多中心(20个中心),样本量1639例。
  • 主要终点TVF:糖尿病患者发生率显著高于非糖尿病患者(HR 1.86,95%CI 1.33-2.60,P<.001)。
  • 非糖尿病患者:血管内成像引导组TVF发生率4.7% vs 造影引导组12.2%,HR 0.41(95%CI 0.25-0.67),P<.001。
  • 糖尿病患者:血管内成像引导组TVF发生率12.9% vs 造影引导组12.3%,HR 0.97(95%CI 0.60-1.57),P=.90,无显著差异。
  • 交互作用:血管内成像使用与糖尿病对TVF风险的交互作用P=.02。
  • 糖尿病患者亚组:HbA1c≤7.5%且经血管内成像实现支架优化者缺血事件风险HR 0.31(95%CI 0.12-0.82),P=.02。

证据类型、等级与局限

  • 证据类型:随机对照试验的预设二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在非糖尿病患者复杂PCI中,血管内成像引导可降低TVF风险(HR 0.41,95%CI 0.25-0.67,P<.001)。
  • 在糖尿病患者复杂PCI中,血管内成像引导与造影引导的TVF风险无显著差异(HR 0.97,95%CI 0.60-1.57,P=.90)。
  • 作者认为,糖尿病患者接受复杂PCI时,应关注使用血管内成像进行支架优化和血糖控制以改善结局。

指南或共识出处

  • RENOVATE-COMPLEX-PCI试验(ClinicalTrials.gov Identifier: NCT03381872)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Data are limited regarding the effects of intravascular imaging guidance during complex percutaneous coronary intervention (PCI) in patients with diabetes.

OBJECTIVE: To compare the clinical outcomes of intravascular imaging-guided vs angiography-guided complex PCI in patients with or without diabetes.

DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of a subgroup of patients in RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention), an investigator-initiated, open-label multicenter trial, analyzed enrolled patients who underwent complex PCI at 20 sites in Korea from May 2018 through May 2021. Eligible patients were randomly assigned in a 2:1 ratio to undergo either the intravascular imaging-guided PCI or angiography-guided PCI. Data analyses were performed from June 2023 to April 2024.

INTERVENTIONS: Percutaneous coronary intervention was performed either under the guidance of intravascular imaging or angiography alone.

MAIN OUTCOMES AND MEASURES: The primary end point was target vessel failure (TVF), defined as a composite of cardiac death, target vessel-related myocardial infarction, or target vessel revascularization.

RESULTS: Among the 1639 patients included in the analysis (mean [SD] age, 65.6 [10.2] years; 1300 males [79.3%]), 617 (37.6%) had diabetes. The incidence of TVF was significantly higher in patients with diabetes than patients without diabetes (hazard ratio [HR], 1.86; 95% CI, 1.33-2.60; P < .001). Among patients without diabetes, the intravascular imaging-guided PCI group had a significantly lower incidence of TVF compared with the angiography-guided PCI group (4.7% vs 12.2%; HR, 0.41 [95% CI, 0.25-0.67]; P < .001). Conversely, in patients with diabetes, the risk of TVF was not significantly different between the 2 groups (12.9% vs 12.3%; HR, 0.97 [95% CI, 0.60-1.57]; P = .90). There was a significant interaction between the use of intravascular imaging and diabetes for the risk of TVF (P for interaction = .02). Among patients with diabetes, only those with good glycemic control (hemoglobin A1c level ≤7.5%) and who achieved stent optimization by intravascular imaging showed a lower risk of future ischemic events (HR, 0.31; 95% CI, 0.12-0.82; P = .02).

CONCLUSIONS AND RELEVANCE: In this secondary analysis of a subgroup of patients in the RENOVATE-COMPLEX-PCI trial, intravascular imaging guidance reduced the risk of TVF compared with angiography guidance in patients without diabetes (but not in patients with diabetes) during complex PCI. In patients with diabetes undergoing complex PCI, attention should be paid to stent optimization using intravascular imaging and glycemic control to improve outcomes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03381872.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Choi KH, Park TK, Song YB, et al. Intravascular Imaging and Angiography Guidance in Complex Percutaneous Coronary Intervention Among Patients With Diabetes: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 38913377. doi:10.1001/jamanetworkopen.2024.17613

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。